BioSpace News Archive

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB).

Syneos Health® has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients.

Cybin Inc. today announced an agreement with Fluence, a leading continuing education organization in psychedelic therapy, to support the streamlining and scaling of Cybin’s EMBARK facilitator training program.

Capstan Therapeutics, Inc. today announced that Capstan management will participate in the following upcoming industry conferences.

Daxor Corporation, the global leader in blood volume measurement technology, announces it will be exhibiting at the MedAxiom CV Transforum Fall’23 Conference being held at the JW Marriott in Austin, TX from October 5-7, 2023.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target meeting, the industry’s preeminent event on Novel Drug Targets and Technologies.

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, announced that Frank Bedu-Addo, PhD, Chief Executive Officer of PDS Biotech, will present at the LD Micro Main Event XVI being held on October 3-5, 2023, in Los Angeles, CA.

Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) submission for intranasally administered scopolamine gel (DPI-386 Nasal Gel).

Armata Pharmaceuticals, Inc. today announced that the first patient has been dosed in the Phase 2a portion of the Company’s diSArm study of AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Initiation of the Phase 2a portion of the study follows Data Review Committee (DRC) review of positive safety and tolerability data from the Phase 1b portion.

Satio is pleased to announce a $3.5 million Small Business Innovation Research (SBIR) contract awarded by the Advanced Research Projects Agency for Health (ARPA-H), National Institutes of Health, Department of Health and Human Services.